PURPOSE: To evaluate the long-term efficacy/tolerability of the ketogenic diet (KD) in paediatric drug-resistant epilepsies. METHODS: Data from children who were treated between 1999 and 2008 and had continuous follow-up of at least 6 months after initiation of the KD were analysed retrospectively. Response was defined as > or = 50% seizure reduction. Treatment effects on EEG, developmental outcome and the "outcome-predictive" value of various clinical factors were also assessed. RESULTS: 50 children (22 boys; mean age 4.5 years+/-3.55) were included. Mean follow-up was 3.93+/-2.95. 50% of the patients were responders, 48% of them became seizure free. 50% were non-responders, 20% of them deteriorated. In responders, EEG background activity improved significantly (p=0.014) and a significantly lower rate of epileptic discharges (p=0.009) was seen after 6 months. In addition, neurological examination findings demonstrated significant developmental progress (p=0.038). Favourable treatment outcome was associated with a shorter disease duration (p=0.025) and generalised tonic clonic seizures (p=0.059). No further significant outcome predictors were detected. However, response was 44% in patients with infantile spasms, 62.5% in those with Dravet syndrome and 50% in Lennox-Gastaut-syndrome. Side effects occurred in 28%, but discontinuation of the KD was not required in any case. They most often observed with concomitant topiramate (p=0.001) and valproate (p=0.046). CONCLUSION: Despite the retrospective nature of the study and the inhomogeneous patient sample, we found good long-term effects of the KD on seizure frequency, EEG and neurological development. 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
PURPOSE: To evaluate the long-term efficacy/tolerability of the ketogenic diet (KD) in paediatric drug-resistant epilepsies. METHODS: Data from children who were treated between 1999 and 2008 and had continuous follow-up of at least 6 months after initiation of the KD were analysed retrospectively. Response was defined as > or = 50% seizure reduction. Treatment effects on EEG, developmental outcome and the "outcome-predictive" value of various clinical factors were also assessed. RESULTS: 50 children (22 boys; mean age 4.5 years+/-3.55) were included. Mean follow-up was 3.93+/-2.95. 50% of the patients were responders, 48% of them became seizure free. 50% were non-responders, 20% of them deteriorated. In responders, EEG background activity improved significantly (p=0.014) and a significantly lower rate of epileptic discharges (p=0.009) was seen after 6 months. In addition, neurological examination findings demonstrated significant developmental progress (p=0.038). Favourable treatment outcome was associated with a shorter disease duration (p=0.025) and generalised tonic clonic seizures (p=0.059). No further significant outcome predictors were detected. However, response was 44% in patients with infantile spasms, 62.5% in those with Dravet syndrome and 50% in Lennox-Gastaut-syndrome. Side effects occurred in 28%, but discontinuation of the KD was not required in any case. They most often observed with concomitant topiramate (p=0.001) and valproate (p=0.046). CONCLUSION: Despite the retrospective nature of the study and the inhomogeneous patient sample, we found good long-term effects of the KD on seizure frequency, EEG and neurological development. 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Authors: Sudha Kilaru Kessler; Paul R Gallagher; Renée A Shellhaas; Robert R Clancy; A G Christina Bergqvist Journal: Epilepsy Res Date: 2011-02-23 Impact factor: 3.045
Authors: Stacey B B Dutton; Nikki T Sawyer; Franck Kalume; Patricia Jumbo-Lucioni; Karin Borges; William A Catterall; Andrew Escayg Journal: Epilepsia Date: 2011-07-29 Impact factor: 5.864
Authors: Markus Breu; Chiara Häfele; Petra Trimmel-Schwahofer; Wolfgang M Schmidt; Franco Laconne; Julia Vodopiutz; Christoph Male; Anastasia Dressler Journal: Epilepsia Date: 2021-08-28 Impact factor: 6.740
Authors: Theresa A Lusardi; Kiran K Akula; Shayla Q Coffman; David N Ruskin; Susan A Masino; Detlev Boison Journal: Neuropharmacology Date: 2015-08-06 Impact factor: 5.250
Authors: Markus Breu; Chiara Häfele; Sarah Glatter; Petra Trimmel-Schwahofer; Johann Golej; Christoph Male; Martha Feucht; Anastasia Dressler Journal: Front Neurol Date: 2021-06-03 Impact factor: 4.003